Host erythrocyte polymorphisms and exposure to Plasmodium falciparum in Papua New Guinea. by Fowkes, F.J. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/69991
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
BioMed Central
Page 1 of 8
(page number not for citation purposes)
Malaria Journal
Open AccessResearch
Host erythrocyte polymorphisms and exposure to Plasmodium 
falciparum in Papua New Guinea
Freya JI Fowkes†1,2, Pascal Michon†1,7, Lynn Pilling1, Ruth M Ripley4, 
Livingstone Tavul3, Heather J Imrie1, Caira M Woods2, Charles S Mgone5,9, 
Adrian JF Luty6,8 and Karen P Day*1,2
Address: 1The Peter Medawar Building for Pathogen Research, Department of Zoology, University of Oxford, UK, 2Department of Medical 
Parasitology, New York University School of Medicine, New York, USA, 3Papua New Guinea Institute of Medical Research, Madang, Papua New 
Guinea, 4Department of Statistics, University of Oxford, UK, 5African Malaria Network Trust, Dar es Salaam, Tanzania, 6Department of 
Parasitology, Institute for Tropical Medicine, University of Tübingen, Tübingen, Germany, 7PNG Institute of Medical Research, Madang, Papua 
New Guinea, 8Medical Parasitology, MMB-NCMLS, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands and 9European 
Developing Countries Clinical Trials Partnership, Tygerberg, Cape Town, South Africa
Email: Freya JI Fowkes - fowkes@wehi.edu.au; Pascal Michon - pmichon@datec.net.pg; Lynn Pilling - lynnpilling@hotmail.com; 
Ruth M Ripley - ruth@stats.ox.ac.uk; Livingstone Tavul - ltavul@pngimr.org.pg; Heather J Imrie - h.imrie@ntlworld.com; 
Caira M Woods - cmw364@med.nyu.edu; Charles S Mgone - mgone@edctp.org; Adrian JF Luty - a.luty@mmb.umcn.nl; 
Karen P Day* - karen.day@med.nyu.edu
* Corresponding author    †Equal contributors
Abstract
Background: The protection afforded by human erythrocyte polymorphisms against the malaria
parasite, Plasmodium falciparum, has been proposed to be due to reduced ability of the parasite to
invade or develop in erythrocytes. If this were the case, variable levels of parasitaemia and rates of
seroconversion to infected-erythrocyte variant surface antigens (VSA) should be seen in different
host genotypes.
Methods: To test this hypothesis, P. falciparum parasitaemia and anti-VSA antibody levels were
measured in a cohort of 555 asymptomatic children from an area of intense malaria transmission
in Papua New Guinea. Linear mixed models were used to investigate the effect of α+-thalassaemia,
complement receptor-1 and south-east Asian ovalocytosis, as well as glucose-6-phosphate
dehydrogenase deficiency and ABO blood group on parasitaemia and age-specific seroconversion
to VSA.
Results: No host polymorphism showed a significant association with both parasite prevalence/
density and age-specific seroconversion to VSA.
Conclusion: Host erythrocyte polymorphisms commonly found in Papua New Guinea do not
effect exposure to blood stage P. falciparum infection. This contrasts with data for sickle cell trait
and highlights that the above-mentioned polymorphisms may confer protection against malaria via
distinct mechanisms.
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Background
Human erythrocyte polymorphisms have long been
thought to play a role in resistance to malaria. High fre-
quencies of host erythrocyte polymorphisms such as α+-
thalassaemia, haemoglobin (Hb) S, Hb C, Hb E, comple-
ment receptor-1 (CR1) deficiency, glucose-6-phosphate
dehydrogenase (G6PD) deficiency and south-east Asian
ovalocytosis (SAO) are found in malaria endemic areas.
Case-control studies have demonstrated that these poly-
morphisms reduce the risk of severe falciparum malaria
rather than mild malaria [1-22]. Experimentally, research
has focused on examining the interactions between the
parasite and the erythrocyte to try to understand possible
mechanisms of protection of these polymorphisms. In
vitro experiments have suggested reduced ability of Plas-
modium falciparum to invade or sustain growth in abnor-
mal erythrocytes [23]. Enhanced clearance of infected
erythrocytes by phagocytosis, and increased enhanced
susceptibility of P. falciparum-infected abnormal erythro-
cytes to oxidative stress, have also been proposed [24-28].
It has also been hypothesized that α+-thalassaemia, CR1
deficiency and blood group O may protect via reduced
rosetting [5,21,29-32], the phenomenon whereby non-
parasitized erythrocytes bind to parasitized erythrocytes.
It is well documented that individuals with sickle cell trait
(HbAS) have lower parasite densities compared to HbAA
individuals in asymptomatic, mild and severe malaria
[18-20,33-44]. This, together with the observation that
the time to reappearance of P. falciparum is lower in HbAS
individuals after drug treatment [39], provides compel-
ling evidence for a direct interaction of the parasite with
the HbS containing erythrocytes or of improved immu-
nity controlling the level of parasitaemia in those with
sickle cell trait. However, data on other erythrocyte poly-
morphisms is less clear cut. Clinical studies have rarely
demonstrated differences in parasite density among geno-
types in symptomatic malaria. Epidemiological studies in
asymptomatic individuals are inconsistent. Cross-sec-
tional studies have shown that α+-thalassaemia [45,46],
SAO [47,48], G6PD [49-53] and ABO polymorphisms
(no studies have examined CR1) have reduced parasite
rates/densities while other studies provide no evidence of
an effect of these polymorphisms on parasite densities
[4,11,54-65]. Data from a single time point may not accu-
rately represent exposure to infection and therefore results
of these studies are hard to interpret.
There are two possible ways to measure exposure to
malaria blood stage infection: 1) by comparing parasite
prevalence/density and, 2) by comparing age-specific
antibody seroconversion to major blood stage antigens
among host genotypes. Seroconversion to P. falciparum-
infected erythrocyte variant surface antigens (VSA), which
include P. falciparum erythrocyte membrane protein-1
(PfEMP-1) and rifins, has been shown to be dependent on
the intensity of transmission [66]. Antibody levels in
endemic areas reflect the level of IgG seroconversion to P.
falciparum-infected erythrocyte VSA [67]. Furthermore, a
study in Tanzania showed that insecticide-treated bednets
limited the repertoire of recognized VSA and reduced anti-
body levels [68]. Seroconversion can also be considered as
a marker for the level of cumulative exposure to the para-
site as it increases with age [69]. The more exposure to P.
falciparum children receive in malaria-endemic areas, the
younger children will seroconvert to VSA.
If human erythrocyte polymorphisms were to hamper
invasion and/or growth of the parasite or enhance the
antibody-dependent control of malarial infection, this
should manifest as differences in both mean parasite den-
sities and patterns of age-specific seroconversion to VSA.
The frequency of the host polymorphisms α+-thalassae-
mia, CR1, ABO blood group, SAO and G6PD deficiency
were determined in a group of children from Papua New
Guinea (PNG). Parasitological criteria and levels of anti-
VSA antibodies were measured in these children in two
consecutive surveys, one year apart. The relationship
between these genetic polymorphisms, parasite preva-
lence/density and age-specific antibody seroconversion to
VSA was investigated in a malaria endemic region of PNG.
Methods
Study design and data collection
Details of study design and data collection have been
reported previously [54]. Briefly, a serial cross-sectional
survey was conducted in asymptomatic children living in
villages of the Amele region, Madang Province, PNG,
where intense year-round malaria transmission occurs
[70]. The study took place from November to December
of 1999 and 2000 in 566 children aged 1–17 years. A
serial study design would ensure that any associations
observed with host genotype would be less likely to have
occurred by chance. Blood samples were collected using
Vacutainer® tubes (Becton Dickinson, UK) and EDTA as
anti-coagulant. A small aliquot of whole blood was blot-
ted onto Isocode® Stix (Schleicher & Schuell GmbH, Das-
sel, Germany) following the manufacturer's instructions,
for further human genetic analyses. The remaining blood
was centrifuged and separated into plasma (stored at -
80°C), buffy coat and erythrocyte pellet, both stored in
guanidine hydrochloride at 4°C. 555 paired samples were
available for antibody determination.
DNA polymorphism analysis
α+-Thalassaemia genotype was determined by polymerase
chain reaction [54]. SAO genotyping was conducted as
described earlier [71] using human DNA from Isocode®
Stix. G6PD deficiency was evaluated qualitatively (Sigma
Diagnostics visual colourimetric assay) and ABO blood
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groups were determined using anti-A and anti-B antibod-
ies from a kit (BIOSCOT, Edinburgh, Scotland). CR1 gen-
otype was determined by polymerase chain reaction and
restriction fragment length polymorphism digest with
HindIII as previously described with modifications [5,72].
Parasites
P. falciparum isolate PNG/M 12, was collected from a child
presenting with acute symptomatic malaria at an aid post
in Madang, during a longitudinal cohort study from
1990/91 [73]. Erythrocytes were washed three times after
buffy coat depletion in RPMI 1640 media buffered with
25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid (HEPES) and supplemented with 25 mM sodium
bicarbonate, 2 mM L-glutamine, 300 mM hypoxanthine
and 10 μg/ml gentamicin (Gibco, UK) (RPMI-HEPES),
and cryopreserved in liquid nitrogen for adaptation in
Oxford. Parasites were cultured in vitro using the method
of Trager and Jensen [74] with modifications [75]. Cells
were grown in RPMI/HEPES supplemented with 10% AB
serum (from donors residing in a non-malarious area), in
an atmosphere of 5% CO2, 2% O2, and 93% N2, sub-cul-
tured into O positive erythrocytes (Oxford Blood Transfu-
sion Service, UK) and stabilates frozen down. Adaptation
and maintenance of PfEMP-1 expressing lines were made
following a previously published method [67].
Surface Immunofluorescence Assay (SIFA)
Detection of antibodies bound to the surface of infected
erythrocytes (IE) have previously been described [67].
Briefly, trophozoites were synchronized and enriched by
Plasmagel® (Laboratoire Roger Bellon, France) flota-
tion[76]. After washing 2× in RPMI and 1× with human
tonicity phosphate-buffered saline (HTPBS)/1% BSA
(Sigma, UK), trophozoite-IE were adjusted to 10 – 15%
parasitaemia. Fifty μl of 1/50 dilution of plasma was
added to 5 μl packed cell volume of IE and incubated for
30 mins at RT. All washes between each step were done 3×
with HTPBS/1% Bovine serum albumin (BSA). The next
antibody layer was a rabbit anti-human IgG (Dako, UK)
(1/100 dilution). The final antibody layer was a 1/100
dilution of FITC-coupled swine anti-rabbit IgG (Dako,
UK) containing 50 μg/ml ethidium bromide. Cells were
fixed for 1 h with 0.5% paraformaldehyde diluted in
HTPBS/1% BSA, then washed 1× and resuspended with
HTPBS. Samples were read on a FACSCalibur™ flow
cytometer (Becton Dickinson, UK): 1000 IE were counted
using the program CELLQUEST™ 3.3 (Becton Dickinson,
UK) for Macintosh. A hyper immune plasma (HIP) pool
from 10 adult residents from Madang and normal human
serum (NHS) from three non malaria-exposed Europeans
(Oxford Blood Transfusion Service, UK) were used as pos-
itive and negative controls, respectively, as previously
described [67]. The percentage of IE staining positive for
human plasma was calculated relative to the response to
HIP and NHS as described earlier [67].
Statistical analysis
Due to the repeated measures study design, appropriate
statistical tests were chosen to analyze paired data. The
association of host polymorphisms and P. falciparum pres-
ence in no surveys, one survey and two surveys was
assessed by ordinal regression with adjustments for age.
Differences in frequency of positive slides were assessed
using χ2 tests for each study year. Linear mixed models
were used to examine the variation of parasite density
among host genotypes with adjustments for age. Linear
mixed models were also used to investigate the effect of
age, parasite density and genotype on antibody levels: the
two values were treated as a repeated measure with a het-
erogeneous compound symmetry covariance structure.
Since the antibody levels showed considerable hetero-
scedasticity, they were transformed before analysis, using
the transformation log(antibody + 2.5). The P. falciparum
counts were transformed by log(P. falciparum + 1) to
reduce skewness while leaving the zero values unchanged.
The models examined the effect of P. falciparum (loga-
rithm of density), age (continuous), and either α+-thalas-
saemia genotype, CR1 genotype, ABO blood group (four
categories [A, B, AB, O] and two categories [O and non-
O]), SAO genotype or G6PD phenotype (three categories
[normal, intermediate, deficient] and two categories [nor-
mal, abnormal]). Interactions between host erythrocyte
polymorphisms were also examined but some subgroups
obtained were too small for reliable analysis. An interac-
tion between sex and G6PD deficiency was also examined
as G6PD deficiency is an X-linked disorder [77]. CR1
expression has been shown to be associated with α+-tha-
lassaemia genotype [5], therefore adjustments were made
for the respective polymorphism in ordinal regression and
mixed linear analysis. Addition of each polymorphism in
each analysis did not alter the final result so no adjust-
ments were made in the final models. The models were
developed using R 1.8.1 [78] and SPSS (version 12.0) and
variables with p-values < .05 were considered significant.
Informed consent was obtained from subjects and their
parents or guardians. The project received ethical approval
from the PNG Medical Research Advisory Committee and
Institutional Review Board of the New York University
School of Medicine.
Results
Characteristics of study cohort
1,100 blood samples and thick smears were collected
from 555 children aged 1–17 years (mean age 9.68 ±
0.18) in the Amele region, Madang Province, PNG at two
surveys in November-December of 1999 and 2000.
Thirty-eight percent of samples were slide-positive for P.
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falciparum in both years of the study and 24.7% were
positive for Plasmodium vivax. Only 57 samples (5.2%)
were positive for both P. falciparum and P. vivax. Geomet-
ric mean parasite density of P. falciparum was 680 para-
sites/μl (95% CI 567–814) and parasite density was
negatively correlated with age (β = -0.08, standard error
[SE] 0.02, P = .002).
Table 1 details the frequency of polymorphisms investi-
gated in this study. High frequencies of α+-thalassaemia
were found in this population (92.9%) with a predomi-
nance of the 4.2 deletion allele (frequency = 0.71). The
CR1 L allele was also predominant with a prevalence of
94.6%, whereas the host erythrocyte polymorphisms SAO
and G6PD were relatively uncommon in this population
(< 10%).
Host polymorphisms and P. falciparum prevalence and 
density
Table 1 also details whether a child was P. falciparum pos-
itive for one survey, two surveys or no surveys, according
to host polymorphism. There was no association of α+-
thalassaemia (P > .7), SAO (P = .29) or G6PD deficiency
(P > .3) with P. falciparum prevalence either at both
surveys, after adjustments for age. There was also no
significant association of α+-thalassaemia (P = .78), SAO
(P = .66) or G6PD deficiency (P = .64) with mean parasite
density, after adjustments for age. Children who were
blood group B were less likely to be positive at both sur-
veys compared to those who were blood group O (P =
.005). When P. falciparum prevalence was analysed sepa-
rately for each year, blood group B had a significantly
lower prevalence of P. falciparum (27.8%) compared to O
(43.3%) in 2000 only (P = .02). There was no significant
difference in mean parasite densities between ABO blood
groups (P ≤ .4) as assessed by a mixed linear model, with
adjustments for age. Children with the CR1 HL genotype
were more likely to be P. falciparum positive for both sur-
veys compared to HH individuals but this was of border-
line significance (P = .07). There was also weak evidence
of CR1 HH genotype having lower geometric mean para-
site densities (322 P. falciparum/μl, 95%CI 129–807)
compared to those who were HL (786 P. falciparum/μl,
95% CI 584–1058, P = .07) or LL genotype (688 P. falci-
parum/μl, 95% CI 540–876, P = .12).
Host polymorphisms and age-specific seroconversion to 
VSA
A multivariate linear mixed model was used to examine
the effect of age and parasitaemia on antibody levels
Table 1: Host polymorphism and parasitological data for 555 children from the Amele region, Papua New Guinea
P. falciparum Prevalencea
Host Polymorphism Negative Positive Positive
Frequency Both surveys One survey Both surveys Pb
n (%) n (%) n (%) n(%)
α+-Thalassaemia
(αα/αα) 39 (7.1) 15 (38.5) 19 (48.7) 5 (12.8) .
(-α/αα) 205 (36.9) 75 (37.1) 94 (46.5) 33 (16.3) 0.72
(-α/-α) 311(56.0) 125 (41.7) 120 (40.0) 55 (18.3) 0.99
CR1c
HH 29 (5.4) 14 (48.3) 12 (41.4) 3 (10.3) .
HL 188 (35.5) 70 (38.0) 78 (42.4) 36 (19.6) 0.07
LL 313 (59.1) 121 (39.9) 133 (43.9) 49 (16.2) 0.11
ABOc
O 180 (32.6) 69 (39.4) 66 (37.7) 40 (22.9) .
non-O 372 (67.4) 145 (39.9) 165 (45.5) 53 (14.6) 0.09
A 178 (32.2) 62 (35.6) 80 (46.0) 32 (18.4) 0.83
B 138 (25.0) 62 (46.6) 58 (43.6) 13 (9.8) 0.005
AB 56 (10.1) 21 (37.5) 27 (48.2) 8 (14.3) 0.27
SAOc
Normal 506 (91.2) 200 (40.4) 211 (42.6) 84 (17.0) .
SAO 49 (8.8) 15 (32.6) 22 (47.8) 9 (19.6) 0.29
G6PDc
Normal 477 (89.7) 182 (39.1) 199 (42.7) 85 (18.2) .
Intermediate 20 (3.8) 8 (44.4) 6 (33.3) 4 (22.2) 0.76
Deficient 35 (6.6) 16 (45.7) 16 (45.7) 3 (8.6) 0.36
a Missing data: 1999, n = 1; 2000, n = 21.
b Differences in frequency of positive slides were assessed using ordinal regression with adjustments for age.
c Abbreviations: CR1, Complement receptor 1; SAO, Southeast Asian Ovalocytosis; G6PD, Glucose-6-phosphate dehydrogenase deficiency. With 
the exception of SAO, these variables contain missing values.
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in samples from the cohort. Both age (β = 0.16, SE 0.009,
P < .001) and parasitaemia (β = 0.03, SE 0.007, P < .001)
were found to positively influence antibody levels. This
model was then applied to each of the five host erythro-
cyte polymorphisms investigated in this study. There was
no significant difference in the age-dependent acquisition
of VSA-specific antibodies with respect to ABO blood
groups (P ≥ .39), SAO (P = .39), or CR1 genotype (P =
.99). There was also no significant difference in age-
dependent seroconversion in children with G6PD
deficiency (P > .2), nor was there evidence of an interac-
tion between G6PD deficiency and sex (P = .16). There
was an effect of α+-thalassaemia on age-dependent anti-
VSA antibody acquisition (Figure 1). Children who were
heterozygous for α+-thalassaemia had a slower rate of
antibody acquisition compared to children of normal
genotype (P = .02). There was no significant difference in
rate of antibody acquisition between children of normal
genotype and those that were homozygous for α+-thalas-
saemia (P = .14).
Discussion
This study investigated age-specific antibody seroconver-
sion in Amele villages on the north coast of PNG, where
malaria transmission is intense [70]. The sample size of
the study was sufficiently large to allow us to look for
interactions among the most common polymorphisms.
Age was positively correlated with seroconversion to VSA,
reflecting the association of age with exposure to malaria
[66]. Parasitaemia was also positively correlated with VSA
antibody levels. This result is similar to what has previ-
ously been shown in asymptomatic African populations
to heterologous VSA [79]. It is therefore essential to make
appropriate adjustments for age and parasitaemia when
examining the association of host erythrocyte polymor-
phisms with age-specific antibody seroconversion.
Papua New Guinean children who are homozygous, but
not heterozygous, for α+-thalassaemia are protected
against severe malaria [1]. These children have signifi-
cantly smaller erythrocytes compared to children of nor-
mal genotype, whereas erythrocyte parameters in
heterozygotes are indistinguishable from normal individ-
uals [80]. If there is a reduced physical interaction
(i.e reduced invasion/growth, rosetting) or enhanced
immune-mediated response between microcytic erythro-
cytes and P. falciparum, then a difference in parasite prev-
alence/density and seroconversion would be expected
between homozygous children and those of normal gen-
otype. This study showed there was no significant differ-
ence in age-specific seroconversion among these
genotypes. Furthermore, there was no significant differ-
ence in P. falciparum density between α+-thalassaemia
genotypes which is in concordance with other studies in
children with asymptomatic parasitaemia [4,11,60-62].
There was some evidence of children of normal genotype
having increased exposure compared to children who
were heterozygous, but not homozygous, for α+-thalassae-
mia. This was surprising given that erythrocyte indices for
heterozygotes are similar to children of normal genotype
[80]. There is strong evidence that α+-thalassaemia confers
particular protection against severe malarial anaemia.
This must be independent of parasite density which has
shown to be similar among α+-thalassaemia genotypes in
children with acute malaria [1-4].
CR1 deficiency and blood group O are thought to protect
against malaria by decreased rosetting. A positive correla-
tion has been shown between rosetting and P. falciparum
parasitaemia and it has been proposed that rosetting may
enhance parasite survival by facilitating invasion and pro-
moting immune evasion [81]. Polymorphisms associated
with increased rosetting such as the CR1 H allele and AB
blood antigens should lead to increased parasitaemia by
this proposed mechanism. Contrary to this expectation,
this study showed weak evidence of children with high
levels of CR1 expression (HH) having lower P. falciparum
prevalence and densities compared to children with lower
CR1 expression (HL or LL genotype). This result could
have occurred by chance given that only 15 children
with HH were P. falciparum positive during the study.
There was also evidence of blood group B having lower P.
Age-specific seroconversion to P. falciparum-infected eryth-rocyte var ant surface antigens according to α+-thalassaemia genotypeFigure 1
Age-specific seroconversion to P. falciparum-infected 
erythrocyte variant surface antigens according to α+-
thalassaemia genotype. Antibody levels are expressed as 
the percentage relative response to a hyper-immune plasma 
control (HIP). Data represent the predicted antibody levels 
from a mixed linear model including age, P. falciparum parasi-
taemia (with parasitaemia set to 0) and α+-thalassaemia geno-
type. There was statistical significance between children of 
normal genotype and children heterozygous for α+-thalassae-
mia only (P = 0.02).
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falciparum prevalence in the 2000 survey, but there was no
significant difference in parasite densities among ABO
blood groups. Neither ABO blood group and CR1 geno-
type had no effect on age-dependent seroconversion to
anti-VSA antibodies, indicating that differences in parasi-
tological data in these groups must have been due to
chance. This study would support the hypothesis that
ABO blood group and CR1 deficiency associated with the
L allele protect against malaria by reduced rosetting and
associated pathology rather than parasite density.
There was no significant difference in geometric mean
parasite densities or rates of seroconversion to P. falci-
parum VSA with respect to G6PD and SAO genotypes.
These data conflict with several studies that have pro-
posed that innate resistance to malaria involved the ina-
bility for the malaria parasite to grow in and/or invade
G6PD deficient and SAO erythrocytes [23]. There was also
no evidence of an interaction between G6PD deficiency
and sex with respect to anti-VSA seroconversion. A recent
case-control study demonstrated that males, but not
females, with G6PD deficiency were protected against
severe malaria [12], but there was no significant difference
in parasite density. Results presented here concur with this
latter observation.
Conclusion
Data presented here highlight the importance of measur-
ing malaria exposure at two time points to investigate the
interactions of host polymorphisms with the malaria par-
asite. Results can occur by chance, and previous studies
have reported data from a single time point. No polymor-
phism showed both a reduction in parasite prevalence/
density and age-specific seroconversion to anti-VSA anti-
bodies. We interpret these findings to indicate that the
mechanisms of protection by these polymorphisms are
not fully explained by either structural aspects of the
erythrocyte preventing infection or by enhanced immune
responses to VSA. Our observations from PNG differ sig-
nificantly from those we and others have seen for African
children with HbAS and/or Hb C carriers. HbAS individu-
als have lower parasite prevalence/densities and delayed
time to reinfection, as well as increased prevalence of anti-
VSA antibodies, compared to those of normal genotype
[18,24,36-39,44,82,83]. Whereas HbC carriers exhibit no
differences in parasite density, yet higher immune
responses to VSA [83]. The enhanced immune reactivity in
Hb S and HbC carriers would suggest that protection
against malaria is partially mediated by acquired immu-
nity. Conversely, the polymorphisms investigated in PNG
may confer protection against the clinical pathologies of
P. falciparum infection by a mechanism that does not
influence parasite density or immunity to VSA.
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